RecruitingCRC (Colorectal Cancer)
Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The EpiDRIVE study aims to identify cfDNA-based epigenetic determinants of response in metastatic colorectal cancer (mCRC) patients treated with EGFR- or VEGF-targeted therapy. By integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to develop a predictive biomarker panel capable of differentiating responders from non-responders to targeted therapy.
Sponsor: City of Hope Medical Center
You may qualify if…
- ✓ Histologically confirmed metastatic colorectal adenocarcinoma (mCRC).
- ✓ Received EGFR-targeted therapy (cetuximab/panitumumab) or VEGF-targeted therapy (bevacizumab).
- ✓ Availability of pre-treatment plasma sample for cfDNA analysis.
- ✓ Documented radiologic response evaluation (RECIST 1.1).
- ✓ RAS/BRAF mutation status known.
You may not qualify if…
- ✕ Inadequate cfDNA quality or low cfDNA yield.
- ✕ Non-adenocarcinoma histology.
- ✕ Concurrent or prior other active malignancy.
- ✕ Active inflammatory or autoimmune disease affecting cfDNA methylation profiles.
Where it's recruiting
California
Duarte
Source: ClinicalTrials.gov · NCT07224841 · last updated 2025-11-05